We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Microarray Immunoassay Identifies Patients with Peanut Allergy

By LabMedica International staff writers
Posted on 28 May 2012
An allergy diagnostic method has been developed that could correctly predict symptomatic peanut allergy by using peptide microarray immunoassays and bioinformatic methods.

Peanut allergy is relatively common, typically permanent, and often severe and a laboratory test that could accurately diagnose symptomatic peanut allergy would greatly facilitate clinical practice. More...


Scientists at the Mount Sinai School of Medicine, (New York, NY, USA) recruited selectively 62 children and adolescents from a larger group of referred patients for the evaluation of peanut allergy between 2001 and 2007. Of the 62 patients, 31 had symptomatic peanut allergy and 31 had outgrown their peanut allergy or were sensitized, but were clinically tolerant to peanut.

A peptide microarray immunoassay was used to compare immunoglobulin E (IgE) and IgG4 binding to the peptides of three major peanut allergens between those with symptomatic peanut allergy and those who had outgrown their allergy or were sensitized but clinically tolerant to peanut ingestion. Specific IgE and IgG4 binding to 419 overlapping peptides covering the amino acid sequences of Arachis hypogaea (Ara h) allergens Ara h 1, Ara h 2, and Ara h 3 were measured by using a peptide microarray immunoassay. Bioinformatic methods were applied for data analysis. The library of overlapping peptides was printed in two sets of duplicates onto Arrayit SuperEpoxy glass slides (Arrayit Corporation, Sunnyvale, CA, USA).

The patients who had symptomatic peanut allergy showed significantly greater IgE binding and broader epitope diversity than did peanut-tolerant individuals. No significant difference in IgG4 binding was found between groups. By using machine-learning methods, four peptide biomarkers were identified and prediction models that can predict the outcome of double blind, placebo-controlled food challenges with high accuracy were developed by using a combination of the biomarkers.

The authors concluded that the novel diagnostic approach could predict peanut allergy with high accuracy by combining the results of a peptide microarray immunoassay and bioinformatic methods. However, they note that further studies are needed to validate the efficacy of this assay in clinical practice. The study was published on in the May 2012 issue of the Journal of Allergy and Clinical Immunology.

Related Links:
Arrayit Corporation
Mount Sinai School of Medicine



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
New
Nucleic Acid Purification Instrument
QIAsymphony Connect
New
Automated Immunoassay Analyzer
SuperFlex™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Shutterstock

Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes

Secondary prevention after myocardial infarction or stroke relies on antiplatelet therapy, yet responses vary widely and both recurrent thrombosis and bleeding remain persistent risks. In the United Kingdom,... Read more

Molecular Diagnostics

view channel
Image: Signatera uses ctDNA analysis to identify residual tumor-derived genetic material after definitive treatment (image credit: Adobe Stock)

Blood-Based MRD Test Predicts Recurrence Risk After Lung Cancer Surgery

Assessing recurrence risk after surgery for early-stage non-small cell lung cancer remains challenging, complicating adjuvant therapy and surveillance decisions. Blood-based molecular residual disease... Read more

Microbiology

view channel
Image: Type 1 diabetes affects more than 9 million people worldwide and can begin years before symptoms appear, making early identification of at-risk children difficult (Image Credit: iStock)

Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk

Type 1 diabetes (T1D) affects more than 9 million people worldwide, including 1.8 million children and adolescents, and often begins years before symptoms appear. Early identification of children who are... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.